Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | BRS3 | P32247 | 1/20 | 0.54 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.53 |
| ▸ | HNF4A | P41235 | 1/20 | 0.53 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | BAD | Q92934 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.49 |
| ▸ | FABP3 | P05413 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7605048 | 0.98 | SLC6A4 (0.62) | SLC6A4SLC6A3BRS3LTB4R2HNF4A | |
| SCHEMBL18759613 | 0.89 | HNF4A (0.63) | LTB4R2HNF4ABCAT2ALDH1A1ALOX15 | |
| SCHEMBL30292805 | 0.89 | HNF4A (0.63) | LTB4R2HNF4ABCAT2ALDH1A1ALOX15 | |
| SCHEMBL11554621 | 0.87 | HNF4A (0.61) | SLC6A3LTB4R2HNF4ABCAT2ALDH1A1 | |
| SCHEMBL28231510 | 0.86 | SLC6A3 (0.66) | SLC6A4SLC6A3BRS3LTB4R2BCAT2 | |
| SCHEMBL32677772 | 0.85 | HNF4A (0.64) | BRS3LTB4R2HNF4ABCAT2MAPT | |
| SCHEMBL505412 | 0.85 | HNF4A (0.64) | BRS3LTB4R2HNF4ABCAT2MAPT | |
| SCHEMBL32677769 | 0.85 | HNF4A (0.64) | BRS3LTB4R2HNF4ABCAT2MAPT | |
| SCHEMBL133057 | 0.85 | HNF4A (0.69) | LTB4R2HNF4ABCAT2ALDH1A1ALOX15 | |
| Benzene SCHEMBL1403559 | 0.85 | HNF4A (0.69) | LTB4R2HNF4ABCAT2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552022-B1 | Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | claimed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | claimed |
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | GLUETACS THERAPEUTICS SHANGHAI CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| US-20250051310-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4058448-B1 | HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| WO-2024032689-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-02-15 | — | — | WO | disclosed |
| EP-4056557-B1 | BENZAZEPINE DERIVATIVES USEFUL AS MEDICAMENTS | OTSUKA PHARMA CO LTD (JP) | 2023-11-22 | — | — | EP | disclosed |
| US-6197798-B1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN | NOVARTIS AG (CH) | 2001-03-06 | — | — | US | disclosed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000005201-A1 | N-BENZOCYCLOALKYL-AMIDE DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-02-03 | — | — | WO | disclosed |
| WO-1998050030-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998050031-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
| EP-0580122-B1 | 4-Fluorophenylbenzoates and liquid crystal compositions containing them | CITIZEN WATCH CO LTD (JP) | 1997-05-28 | — | — | EP | disclosed |
| EP-0059983-B1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR USE AS A MEDICAMENT | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-06-11 | — | — | EP | disclosed |
| US-4578522-A | CHEMICAL INTERMEDIATES FOR BLOOD LIPID CONTROLLING COMPOUNDS | BURROUGHS WELLCOME CO. | 1986-03-25 | — | — | US | disclosed |
| EP-0059983-A1 | Substituted biphenyl compounds for use as a medicament | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | CDR2, CYC1, CLN6 | SLC6A4 2363/4885SLC6A3 1375/4885BRS3 3026/4885 |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | ADAMTS7, MMP7, ADAM17 | SLC6A4 1821/4885SLC6A3 1469/4885BRS3 160/4885 |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | SLC6A4 516/4885SLC6A3 477/4885BRS3 45/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | SLC6A4 516/4885SLC6A3 477/4885BRS3 45/4885 |
| US-20250051310-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | SLC6A4 344/4885SLC6A3 277/4885BRS3 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.